Literature DB >> 30283089

A gender-specific association of the polymorphism Ile197Met in the kininogen 1 gene with plasma irbesartan concentrations in Chinese patients with essential hypertension.

Shengnan Hu1,2, Jun Cheng1, Justin Weinstock3, Xiu Fan1, Scott A Venners4, Yi-Hsiang Hsu5,6, Faming Pan7, Xiangdong Zha1, Jinlu Sun8, Shanqun Jiang9,10,11, Xiping Xu12,13.   

Abstract

This study was conducted to explore interactions in the association of the kininogen (KNG1) Ile197Met polymorphism and gender with plasma concentrations of irbesartan in Chinese patients with essential hypertension. A total of 1100 subjects with essential hypertension received a daily oral dose of 150 mg irbesartan for twenty-eight consecutive days. High-performance liquid chromatography-fluorescence (HPLC) was used to detect plasma irbesartan concentrations on day 28. The KNG1 Ile197Met gene polymorphism was determined using high-throughput TaqMan technology. The frequency distribution of KNG1 Ile197Met genotype conformed to the Hardy-Weinberg equilibrium. After 28 days of treatment, patients with the GG genotype had significantly lower irbesartan concentrations (P = 0.033) compared to homozygous TT genotype carriers. After stratifying by gender, male G allele carriers had significantly lower irbesartan concentrations (GG, P = 0.015; TG, P = 0.015, respectively) relative to TT genotype after adjusting for age, region, body mass index (BMI), smoking, and alcohol consumption. However, there was no significant difference in female subjects. A further test for a multiplicative interaction between the KNG1 Ile197Met polymorphism and gender in association with ln-plasma irbesartan concentrations in a multiple linear regression model was also significant (P for interaction = 0.033). This is the first study to suggest that gender may influence the association of the Ile197Met variant of KNG1 with ln-plasma irbesartan concentration. This finding may indicate that the interaction of gender and the KNG1 Ile197Met gene polymorphism can influence plasma trough irbesartan concentrations, which may contribute to a better development of personalized hypertensive treatment in Chinese patients.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30283089     DOI: 10.1038/s41371-018-0119-1

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  32 in total

1.  Identification of cis-regulatory variation influencing protein abundance levels in human plasma.

Authors:  Anbarasu Lourdusamy; Stephan Newhouse; Katie Lunnon; Petra Proitsi; John Powell; Angela Hodges; Sally K Nelson; Alex Stewart; Stephen Williams; Iwona Kloszewska; Patrizia Mecocci; Hilkka Soininen; Magda Tsolaki; Bruno Vellas; Simon Lovestone; Richard Dobson
Journal:  Hum Mol Genet       Date:  2012-05-16       Impact factor: 6.150

Review 2.  Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development.

Authors:  S-M He; Z-W Zhou; X-T Li; S-F Zhou
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

3.  Individual and joint association of alpha1A-adrenergic receptor Arg347Cys polymorphism and plasma irbesartan concentration with blood pressure therapeutic response in Chinese hypertensive subjects.

Authors:  Shanqun Jiang; Guangyun Mao; Shanchun Zhang; Xiumei Hong; Genfu Tang; Zhiping Li; Xue Liu; Yan Zhang; Binyan Wang; Xiping Xu; Xiaobin Wang
Journal:  Clin Pharmacol Ther       Date:  2005-09       Impact factor: 6.875

4.  Kininogens: More than cysteine protease inhibitors and kinin precursors.

Authors:  Gilles Lalmanach; Clément Naudin; Fabien Lecaille; Hans Fritz
Journal:  Biochimie       Date:  2010-03-24       Impact factor: 4.079

5.  Structural organization of the human kininogen gene and a model for its evolution.

Authors:  N Kitamura; H Kitagawa; D Fukushima; Y Takagaki; T Miyata; S Nakanishi
Journal:  J Biol Chem       Date:  1985-07-15       Impact factor: 5.157

6.  Renin inhibitor aliskiren exerts beneficial effect on trabecular bone by regulating skeletal renin-angiotensin system and kallikrein-kinin system in ovariectomized mice.

Authors:  Y Zhang; L Wang; Y Song; X Zhao; M S Wong; W Zhang
Journal:  Osteoporos Int       Date:  2015-10-06       Impact factor: 4.507

Review 7.  Renin-angiotensin-aldosterone system inhibition: overview of the therapeutic use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and direct renin inhibitors.

Authors:  Kelly Mercier; Holly Smith; Jason Biederman
Journal:  Prim Care       Date:  2014-09-29       Impact factor: 2.907

8.  Differential regulation of kininogen gene expression by estrogen and progesterone in vivo.

Authors:  L M Chen; P Chung; S Chao; L Chao; J Chao
Journal:  Biochim Biophys Acta       Date:  1992-06-15

9.  The role of the kallikrein-kinin system genes in the salt sensitivity of blood pressure: the GenSalt Study.

Authors:  Dongfeng Gu; Qi Zhao; Tanika N Kelly; James E Hixson; Dabeeru C Rao; Jie Cao; Jing Chen; Jianxin Li; Jichun Chen; Xu Ji; Dongsheng Hu; Xushan Wang; De-Pei Liu; Jiang He
Journal:  Am J Epidemiol       Date:  2012-10-01       Impact factor: 4.897

10.  Gender-specific association between the kininogen 1 gene variants and essential hypertension in Chinese Han population.

Authors:  Weiyan Zhao; Yaping Wang; Laiyuan Wang; Xiangfeng Lu; Wei Yang; Jianfeng Huang; Shufeng Chen; Dongfeng Gu
Journal:  J Hypertens       Date:  2009-03       Impact factor: 4.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.